Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
David M. Herrington, David M. Reboussin, K. Bridget Brosnihan et al. · New England Journal of Medicine · 2000
BACKGROUND: Heart disease is a major cause of illness and death in women. To understand better the role of estrogen in the treatment and prevention of heart disease, more information is needed about its effects on coronary atherosclerosis and the extent to which concomitant progestin therapy may modify these effects. METHODS: We randomly assigned a total of 309 women with angiographically verified coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo. The women were followed for a mean (+/-SD) of 3.2+/-0.6 years. Base-line and follow-up coronary angiograms were analyzed by quantitative coronary angiography. RESULTS: Estrogen and estrogen plus medroxyprogesterone acetate produced significant reductions in low-density lipoprotein cholesterol levels (9.4 percent and 16.5 percent, respectively) and significant increases in high-density lipoprotein cholesterol levels (18.8 percent and 14.2 percent, respectively); however, neither treatment altered the progression of coronary atherosclerosis. After adjustment for measurements at base line, the mean (+/-SE) minimal coronary-artery diameters at follow-up were 1.87+/-0.02 mm, 1.84+/-0.02 mm, and 1.87+/-0.02 mm in women assigned to estrogen, estrogen plus medroxyprogesterone acetate, and placebo, respectively. The differences between the values for the two active-treatment groups and the value for the placebo group were not significant. Analyses of several secondary angiographic outcomes and subgroups of women produced similar results. The rates of clinical cardiovascular events were also similar among the treatment groups. CONCLUSIONS: Neither estrogen alone nor estrogen plus medroxyprogesterone acetate affected the progression of coronary atherosclerosis in women with established disease. These results suggest that such women should not use estrogen replacement with an expectation of cardiovascular benefit.
Cited by 1,247 works. doi:10.1056/nejm200008243430801 Open-access PDF
Authors
- David M. Herrington
- David M. Reboussin
- K. Bridget Brosnihan
- Penny C. Sharp
- Sally Ann Shumaker
- Thomas E. Snyder
- Curt Daniel Furberg
- Glen J. Kowalchuk
- Thomas Stuckey
- William John Rogers
- David H. Givens
- David D. Waters
References
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
- Design of the Women’s Health Initiative Clinical Trial and Observational Study
- Can lifestyle changes reverse coronary heart disease?
- Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.
- The Protective Effects of Estrogen on the Cardiovascular System
- Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
- Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins
- Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone.